Mylan’s Lantus biosimilar held up by manufacturing issueMylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient Share XMylan’s Lantus biosimilar held up by manufacturing issuehttps://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in EuropeTwo biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada Share XLilly faces biosimilar rivals to osteoporosis drug Forsteo in Europehttps://pharmaphorum.com/news/lilly-faces-biosimilar-rivals-to-osteoporosis-drug-forsteo-in-europe/
J&J faces FTC probe on Remicade biosimilar defenceJohnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share XJ&J faces FTC probe on Remicade biosimilar defencehttps://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/
Roche raises 2019 outlook, shrugging off biosimilar threatNew product sales helped Roche to a healthy 9% increase in sales in the first half of the Share XRoche raises 2019 outlook, shrugging off biosimilar threathttps://pharmaphorum.com/news/roche-raises-2019-outlook-shrugging-off-biosimilar-threat/
New deals extend Mundipharma biosimilar reachMundipharma has fleshed out its range of biosimilars by acquiring Tuznue, a version of Roche’s breast cancer blockbuster Share XNew deals extend Mundipharma biosimilar reachhttps://pharmaphorum.com/news-market-access/new-deals-extend-mundipharma-biosimilar-reach/
FDA approves Samsung/Merck & Co’s Herceptin biosimilarThe FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck Share XFDA approves Samsung/Merck & Co’s Herceptin biosimilarhttps://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/
Mylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedMylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price Share XMylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedhttps://pharmaphorum.com/news/mylan-and-fujifilm-biosimilar-approved/
Allergan buys Bonti and its Botox successor, as biosimilar loomsAllergan has bought the privately-held biotech Bonti, which has been developing a fast-acting, short duration replacement alternative to Share XAllergan buys Bonti and its Botox successor, as biosimilar loomshttps://pharmaphorum.com/news/allergan-buys-bonti-and-its-botox-successor-as-biosimilar-looms/
Biosimilars underused in rheumatoid arthritis on the NHS – expertsExperts call for lower disease activity threshold for biologic drugs Share XBiosimilars underused in rheumatoid arthritis on the NHS – expertshttps://pharmaphorum.com/news/biosimilars-underused-rheumatoid-arthritis-nhs-experts/